AntriaBio

Financials

Investor Relations

Financials

v3.6.0.2
Consolidated Balance Sheets - USD ($)
Dec. 31, 2016
Jun. 30, 2016
Current assets    
Cash $ 3,573,148 $ 4,062,013
Other current assets 213,441 430,094
Total current assets 3,786,589 4,492,107
Non-current assets    
Fixed assets, net 5,728,844 5,984,670
Intangibile assets, net 47,968 51,614
Deposit 375,000 375,000
Total non-current assets 6,151,812 6,411,284
Total Assets 9,938,401 10,903,391
Current liabilities:    
Accounts payable and accrued expenses 1,530,763 1,500,650
Convertible notes payable 10,000 60,000
Deferred lease liability, current portion 125,214 119,688
Lease payable 0 23,128
Interest payable 2,762 15,079
Warrant derivative liability 1,230 11,955
Total current liabilities 1,669,969 1,730,500
Non-current liabilities:    
Deferred lease liability, less current portion 335,588 400,038
Total non-current liabilities 335,588 400,038
Total Liabilities 2,005,557 2,130,538
Commitments and Contingencies (Note 11)
Stockholders' equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 40,952,450 and 35,110,916 shares issued and outstanding, December 31, 2016 and June 30, 2016 40,954 35,114
Additional paid-in capital 60,640,517 52,782,569
Accumulated deficit (52,748,627) (44,044,830)
Total stockholders' equity 7,932,844 8,772,853
Total Liabilities and Stockholders' Equity $ 9,938,401 $ 10,903,391
v3.6.0.2
Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Research and development        
Compensation and benefits $ 1,909,518 $ 1,142,198 $ 3,213,358 $ 2,007,401
Consultants and outside costs 194,783 340,289 466,258 604,280
Material manufacturing costs 567,430 755,464 1,079,137 1,375,511
Facilities and other costs 403,648 285,926 802,555 504,951
Research and development 3,075,379 2,523,877 5,561,308 4,492,143
General and administrative        
Compensation and benefits 1,285,052 1,170,679 2,151,953 2,117,850
Professional fees 139,865 116,112 286,016 238,173
Investor relations 87,428 57,402 155,535 114,320
General and administrative 301,520 198,466 558,115 403,649
General and administrative 1,813,865 1,542,659 3,151,619 2,873,992
Total operating expenses 4,889,244 4,066,536 8,712,927 7,366,135
Loss from operations (4,889,244) (4,066,536) (8,712,927) (7,366,135)
Other income (expense)        
Interest income 0 193 0 964
Interest expense 0 (1,379) (1,595) (2,992)
Derivative gains 1,313 1,729 10,725 14,316
Total other income (expense) 1,313 543 9,130 12,288
Net loss $ (4,887,931) $ (4,065,993) $ (8,703,797) $ (7,353,847)
Net loss per common share - basic and diluted $ (0.12) $ (0.17) $ (0.23) $ (0.3)
Weighted average number of common shares outstanding - basic and diluted 40,788,241 24,338,219 38,091,406 24,338,219
v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (8,703,797) $ (7,353,847)
Amortization of intangible asset 3,646 3,646
Depreciation expense 546,429 220,537
Stock-based compensation expense 2,125,966 1,965,993
Derivative gains (10,725) (14,316)
Warrant expense 0 21,092
Changes in operating assets and liabilities:    
Decrease in other assets 29,153 65,739
Increase in accounts payable and accrued expenses 12,097 295,965
(Decrease) increase in interest payable (2,800) 1,000
Decrease in deferred lease liability (58,924) (4,098)
Net Cash Used In Operating Activities (6,058,955) (4,798,289)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (272,587) (1,257,542)
Return of security deposit 187,500 187,500
Decrease in restricted cash 0 450,167
Net Cash Used In Investing Activities (85,087) (619,875)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on lease payable (23,128) (46,453)
Proceeds from issuance of equity financing 6,361,499 2,000,115
Payment of placement agent compensation and issuance costs (683,194) (105,715)
Net Cash Provided by Financing Activities 5,655,177 1,847,947
Net decrease in cash (488,865) (3,570,217)
Cash - Beginning of Period 4,062,013 5,278,706
Cash - End of Period 3,573,148 1,708,489
Cash Paid During the Period for:    
Taxes 0 0
Interest 0 0
Non-Cash Transactions:    
Fixed assets acquired through accounts payable and accrued expenses 18,016 511,563
Warrant value recorded as issuance costs 516,550 90,852
Conversion of note payable into common stock 50,000 0
Conversion of interest payable into common stock $ 9,517 $ 0